Avidity Biosciences (RNA) stock price, revenue, and financials

Avidity Biosciences market cap is $739.1 m, and annual revenue was $6.79 m in FY 2020

$739.1 M

RNA Mkt cap, 04-Aug-2021

$6.8 M

Avidity Biosciences Revenue FY, 2020
Avidity Biosciences Net income (FY, 2020)-44.4 M
Avidity Biosciences EBIT (FY, 2020)-44.3 M
Avidity Biosciences Cash, 31-Dec-2020321.5 M
Avidity Biosciences EV418.6 M
Get notified regarding key financial metrics and revenue changes at Avidity BiosciencesLearn more
Banner background

Avidity Biosciences Income Statement

Annual

USDFY, 2020

Revenue

6.8m

R&D expense

37.6m

General and administrative expense

13.5m

Operating expense total

51.1m

EBIT

(44.3m)

EBIT margin, %

(652%)

Investment income

206.0k

Net Income

(44.4m)

Quarterly

USDQ2, 2020Q3, 2020

Revenue

1.5m1.7m

R&D expense

9.0m9.5m

General and administrative expense

2.9m3.8m

Operating expense total

11.9m13.2m

EBIT

(10.4m)(11.5m)

EBIT margin, %

(673%)(657%)

Interest expense

Investment income

18.0k27.0k

Net Income

(10.6m)(11.4m)

Avidity Biosciences Balance Sheet

Annual

USDFY, 2020

Cash

321.5m

Prepaid Expenses

3.5m

Current Assets

331.7m

PP&E

1.5m

Total Assets

333.9m

Accounts Payable

7.7m

Current Liabilities

14.6m

Long-term debt

938.0k

Total Debt

938.0k

Total Liabilities

27.7m

Common Stock

4.0k

Additional Paid-in Capital

372.8m

Retained Earnings

(66.5m)

Total Equity

306.2m

Financial Leverage

1.1 x

Quarterly

USDQ2, 2020Q3, 2020

Cash

352.4m341.1m

Prepaid Expenses

1.4m3.2m

Current Assets

353.8m344.3m

PP&E

771.0k1.3m

Total Assets

355.4m346.1m

Accounts Payable

5.4m6.3m

Current Liabilities

11.6m13.7m

Total Liabilities

25.1m26.0m

Common Stock

4.0k4.0k

Additional Paid-in Capital

369.1m370.4m

Retained Earnings

(38.8m)(50.3m)

Total Equity

330.3m320.2m

Financial Leverage

1.1 x1.1 x

Avidity Biosciences Cash Flow

Annual

USDFY, 2020

Net Income

(44.4m)

Depreciation and Amortization

373.0k

Accounts Payable

5.7m

Cash From Operating Activities

(37.1m)

Purchases of PP&E

(1.1m)

Cash From Investing Activities

(7.8m)

Long-term Borrowings

(4.7m)

Cash From Financing Activities

272.0m

Net Change in Cash

227.1m

Interest Paid

571.0k

Quarterly

USDQ2, 2020Q3, 2020

Net Income

(16.6m)(28.1m)

Depreciation and Amortization

157.0k258.0k

Accounts Payable

1.9m4.4m

Cash From Operating Activities

(14.9m)(24.0m)

Purchases of PP&E

(10.0k)(855.0k)

Cash From Investing Activities

(10.0k)(855.0k)

Long-term Borrowings

(4.7m)(4.7m)

Cash From Financing Activities

272.9m271.6m

Net Change in Cash

258.0m246.7m

Interest Paid

571.0k571.0k

Avidity Biosciences Ratios

USDQ2, 2020

EV/EBIT

-62.4 x

EV/CFO

-43.3 x

Revenue/Employee

42.5k

Financial Leverage

1.1 x